Elemer Piros, Ph.D.

Managing Director, Senior Research Analyst



Elemer Piros, Ph.D. rejoined Roth Capital Partners in June 2020, and is currently a Senior Research Analyst covering the Biotechnology sector. Prior to rejoining ROTH, Dr. Piros was a Senior Biotechnology Analyst at Cantor Fitzgerald between 2015 and 2019. Previously, Dr. Piros was the interim CEO of eMMUNITY, Inc., an immunotherapy startup company; prior to the position at eMMUNITY, Dr. Piros was a publishing Senior Biotechnology Analyst at Rodman & Renshaw and Burrill Securities, covering 80 companies that developed products for CNS disorders, inflammation, and the diagnosis and treatment of cancer.

Previously, Dr. Piros was a buy-side biotechnology analyst at Spear, Leeds & Kellogg, a wholly owned subsidiary of Goldman Sachs. From 1990 to 2000, Dr. Piros conducted academic research in the field of neuroscience, focusing on understanding the molecular mechanism of communication in the nervous system.

Dr. Piros was ranked as the #1 Biotechnology Analyst by the Wall Street Journal in 2006, and by the Financial Times in 2010, both based on stock portfolio performance.


Joined Roth

June 2015

Rejoined Roth

June 2020

Sector Focus